Collectively, these data support the hypothesis that in HER2-amplified colon cancer xenografts treatment with refametinib plus pictilisib is more effective as initial therapy in order to better control the onset of cancer cell resistance mechanisms, that are more frequent and develop earlier with HER2 blockade. The gene discussed is ERBB2; the disease is malignant colon neoplasm.